Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 10/20 | 0.45 |
| ▸ | DRD4 | P21917 | 7/20 | 0.45 |
| ▸ | DRD2 | P14416 | 6/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237465 | 0.94 | GRM2 (0.41) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL4157977 | 0.87 | GRM2 (0.61) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL4139579 | 0.86 | CYP2D6 (0.43) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL4151843 | 0.83 | DRD2 (0.46) | GRM2DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4941482 | 0.81 | LIPG (0.36) | GRM2DRD4DRD2DRD3CXCR3 | |
| SCHEMBL4147399 | 0.81 | MAOB (0.46) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL4154875 | 0.78 | GRM2 (0.72) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL4155735 | 0.76 | GRM2 (0.75) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL4154130 | 0.76 | MAOB (0.43) | ALDH1A1 | |
| SCHEMBL4752511 | 0.76 | CXCR3 (0.35) | GRM2DRD4DRD2CXCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885DRD4 205/4885DRD2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.